Last reviewed · How we verify
Duloxetine or escitalopram — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Duloxetine or escitalopram (Duloxetine or escitalopram) — New York State Psychiatric Institute.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Duloxetine or escitalopram TARGET | Duloxetine or escitalopram | New York State Psychiatric Institute | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Duloxetine or escitalopram CI watch — RSS
- Duloxetine or escitalopram CI watch — Atom
- Duloxetine or escitalopram CI watch — JSON
- Duloxetine or escitalopram alone — RSS
Cite this brief
Drug Landscape (2026). Duloxetine or escitalopram — Competitive Intelligence Brief. https://druglandscape.com/ci/duloxetine-or-escitalopram. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab